Great Valley Advisor Group Inc. Reduces Holdings in Solventum Co. (NYSE:SOLV)

Great Valley Advisor Group Inc. decreased its stake in shares of Solventum Co. (NYSE:SOLV) by 27.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,787 shares of the company’s stock after selling 2,529 shares during the period. Great Valley Advisor Group Inc.’s holdings in Solventum were worth $473,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Deseret Mutual Benefit Administrators purchased a new position in Solventum during the second quarter valued at $25,000. Hollencrest Capital Management bought a new position in shares of Solventum in the 2nd quarter worth about $25,000. Partnership Wealth Management LLC purchased a new position in Solventum during the 2nd quarter valued at about $26,000. Richard W. Paul & Associates LLC bought a new stake in Solventum during the second quarter worth about $26,000. Finally, Family Firm Inc. purchased a new stake in Solventum in the second quarter worth about $26,000.

Solventum Stock Performance

Shares of NYSE SOLV opened at $71.50 on Wednesday. The firm’s 50-day moving average price is $70.51 and its 200-day moving average price is $62.40. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Analysts Set New Price Targets

Several research firms have recently issued reports on SOLV. The Goldman Sachs Group lifted their target price on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a report on Monday, August 12th. BTIG Research assumed coverage on Solventum in a report on Thursday, September 5th. They issued a “neutral” rating on the stock. Wells Fargo & Company reduced their price target on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a report on Friday, August 9th. Morgan Stanley upped their price target on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Finally, Stifel Nicolaus started coverage on shares of Solventum in a report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $68.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.